Print

Fournier Pharma Announces The Receipt Of U.S. FDA Orphan Drug Status For Anatibant For Treatment Of Severe Traumatic Brain Injury 
10/19/2005 5:09:45 PM

Fournier Pharma today announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Anatibant (LF16-0687) for the treatment of patients having experienced a severe traumatic brain injury (Glasgow Coma Scale 3 to 8) in order to decrease early mortality and improve long-term functional and neurological outcome.
//-->